{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:54:25Z","timestamp":1792205665890,"version":"4.4.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clinthera.2015.11.007","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T17:37:05Z","timestamp":1449250625000},"page":"2619-2636","source":"Crossref","is-referenced-by-count":50,"title":["Beyond Vancomycin: The Tail of the Lipoglycopeptides"],"prefix":"10.1016","volume":"37","author":[{"given":"Kenneth P.","family":"Klinker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Borgert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.11.007_bib1","unstructured":"Centers for Disease Control. Antibiotic resistance threats in the United States, 2013. (2013). http:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf. Accessed May 15, 2015."},{"key":"10.1016\/j.clinthera.2015.11.007_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/bmj.1.5219.124-a","article-title":"\u2018Celbenin\u2019-resistant staphylococci","volume":"1","author":"Jevons","year":"1961","journal-title":"Br Med J"},{"key":"10.1016\/j.clinthera.2015.11.007_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.11.007_bib4","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1086\/428616","article-title":"Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia","volume":"40","author":"Mangili","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkr437","article-title":"MRSA: the first half century","volume":"67","author":"Moellering","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1592\/phco.27.7.1001","article-title":"Burden of methicillin-resistant Staphylococcus aureus: Focus on clinical and economic outcomes","volume":"27","author":"Lodise","year":"2007","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.clinthera.2015.11.007_bib7","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3201\/eid1312.070629","article-title":"Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999\u20132005","volume":"13","author":"Klein","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"21","key":"10.1016\/j.clinthera.2015.11.007_bib8","first-page":"1970","article-title":"National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011","volume":"173","author":"Dantes","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2015.11.007_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the national healthcare safety network at the Centers for Disease Control and Prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2015.11.007_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2334-13-252","article-title":"Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a US population: a retrospective population-based study","volume":"13","author":"Ray","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib11","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin\u2010structure infections caused by gram\u2010positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib12","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.11.007_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: The SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib14","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2015.11.007_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1592\/phco.31.5.441","article-title":"Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15\u201320 mg\/L suggested by the vancomycin consensus guidelines","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.clinthera.2015.11.007_bib17","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2015.11.007_bib18","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2015.11.007_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0034-1397040","article-title":"Treatment of methicillin-resistant Staphylococcus aureus: Vancomycin and beyond","volume":"36","author":"Holmes","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2015.11.007_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ja.2014.111","article-title":"Glycopeptide antibiotics: Back to the future","volume":"67","author":"Butler","year":"2014","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.clinthera.2015.11.007_bib21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration\u2010time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"Van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides A comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2015.11.007_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7164\/antibiotics.57.326","article-title":"Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424)","volume":"57","author":"Leadbetter","year":"2004","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.clinthera.2015.11.007_bib25","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/526772","article-title":"Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic","volume":"46","author":"Billeter","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib27","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib28","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: mechanism of action","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.clinthera.2015.11.007_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jmb.2008.01.031","article-title":"Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus","volume":"377","author":"Kim","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1016\/j.clinthera.2015.11.007_bib31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1592\/phco.28.4.458","article-title":"Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections","volume":"28","author":"Leonard","year":"2008","journal-title":"Pharmacother J Hum Pharmacol. Drug Ther"},{"key":"10.1016\/j.clinthera.2015.11.007_bib32","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1093\/cid\/cir923","article-title":"Oritavancin microbiologic features and activity results from the surveillance program in the United States","volume":"54","author":"Mendes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib33","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.diagmicrobio.2011.09.002","article-title":"In vitro time\u2013kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin","volume":"71","author":"Vidaillac","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diagmicrobio.2014.12.011","article-title":"Update of the telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2013), when applying the revised susceptibility testing method","volume":"81","author":"Mendes","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib35","unstructured":"Nichol KA, Adam HJ, Laing N, et al. Activity of telavancin against gram-positive cocci from CANWARD 2007-2013 using previously established and revised CLSI guidelines [C-826]. Poster session presented at: 54th Annual meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy; September 5\u20139, 2014; Washington DC."},{"key":"10.1016\/j.clinthera.2015.11.007_bib36","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1128\/AAC.48.6.2149-2152.2004","article-title":"In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp","volume":"48","author":"Goldstein","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.anaerobe.2004.10.005","article-title":"In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic gram-positive cocci","volume":"11","author":"Citron","year":"2005","journal-title":"Anaerobe"},{"key":"10.1016\/j.clinthera.2015.11.007_bib38","unstructured":"Smart JI, Corey GR, Shorr AF, et al. Phase 3 clinical isolates with reduced susceptibility to vancomycin remain susceptible to telavancin. Poster session presented at: 54th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. September, 2014; Washington DC."},{"key":"10.1016\/j.clinthera.2015.11.007_bib39","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.diagmicrobio.2014.05.014","article-title":"Comparative in vitro activities of dalbavancin and seven comparator agents against 41 staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains","volume":"79","author":"Citron","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib40","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/AAC.47.6.1968-1971.2003","article-title":"In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria","volume":"47","author":"Goldstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","article-title":"Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib42","unstructured":"Mendes RE, Sader HD, Streit JM, et al. In vitro activity of dalbavancin when tested against Streptococcus pneumoniae responsible for documented infections in medical centres in five continents worldwide (2011-2013). Poster presented at: The 25th European Congress of Clinical Microbiology and Infectious Diseases Copenhagen, Denmark; 2015"},{"key":"10.1016\/j.clinthera.2015.11.007_bib43","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.01513-07","article-title":"Effect of polysorbate 80 on oritavancin binding to plastic surfaces: Implications for susceptibility testing","volume":"52","author":"Arhin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib44","series-title":"Vibativ [package insert]","year":"2014"},{"key":"10.1016\/j.clinthera.2015.11.007_bib45","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/AAC.04052-14","article-title":"Baseline activity of telavancin against gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method","volume":"59","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib46","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1093\/cid\/cir924","article-title":"Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections","volume":"54","author":"Arias","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib47","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/AAC.06067-11","article-title":"Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009\u20132010","volume":"56","author":"Mendes","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib48","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1086\/491711","article-title":"Vancomycin resistance in gram-positive cocci","volume":"42","author":"Courvalin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib49","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"124","author":"Gardete","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2015.11.007_bib50","unstructured":"Sahm DF, Benton BM, Jones ME, et al. Telavancin demonstrates a low potential for in vitro selection of resistance among key target gram-positive species [C1-0681]. Poster session presented at: 46th Annual meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy. September 27\u201330, 2006; San Francisco, CA."},{"key":"10.1016\/j.clinthera.2015.11.007_bib51","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1128\/AAC.00742-09","article-title":"Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies","volume":"53","author":"Kosowska-Shick","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib52","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/AAC.00620-06","article-title":"Bactericidal activity and resistance development profiling of dalbavancin","volume":"51","author":"Goldstein","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib53","unstructured":"FDA. FDA Briefing Document for NDA 206334: Oritavancin diphosphate. Microbiology and Virology review. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206334Orig1s000MicroR.pdf. accessed May 31, 2015"},{"key":"10.1016\/j.clinthera.2015.11.007_bib54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2015.01.017","article-title":"Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin","volume":"82","author":"Jones","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib55","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.05098-14","article-title":"Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide","volume":"59","author":"Jones","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.clinthera.2015.11.007_bib56","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JCM.00611-15","article-title":"Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin","volume":"53","author":"Mendes","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2015.11.007_bib57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","article-title":"Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects","volume":"49","author":"Shaw","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib58","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jac\/dkn273","article-title":"Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects","volume":"62","author":"Wong","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib59","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/AAC.00383-11","article-title":"Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function","volume":"56","author":"Lodise","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib60","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.00176-15","article-title":"Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials","volume":"59","author":"Rubino","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib61","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/AAC.05915-11","article-title":"Population pharmacokinetics of telavancin in healthy subjects and patients with infections","volume":"56","author":"Samara","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib62","unstructured":"Duchin K, Shaw J, Seroogy J, et al. Effect of haemodialysis on single dose pharmacokinetics of telavancin [abstract p1028]. Poster session presented at: 14th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Disease. 2005; Copenhagen, Denmark."},{"key":"10.1016\/j.clinthera.2015.11.007_bib63","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/039139880903201006","article-title":"Telavancin and hydroxy propyl-\u03b2-cyclodextrin clearance during continuous renal replacement therapy: An in vitro study","volume":"32","author":"Patel","year":"2009","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.clinthera.2015.11.007_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1592\/phco.30.1.35","article-title":"Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin","volume":"30","author":"Goldberg","year":"2010","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.clinthera.2015.11.007_bib65","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1128\/AAC.50.2.788-790.2006","article-title":"Tissue penetration of telavancin after intravenous administration in healthy subjects","volume":"50","author":"Sun","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib66","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1128\/AAC.00875-07","article-title":"Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics","volume":"52","author":"Gotfried","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.clinthera.2015.11.007_bib67","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: A long-half-life lipoglycopeptide","volume":"61","author":"Saravolatz","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib68","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.5301\/ijao.5000008","article-title":"In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers","volume":"34","author":"Kumar","year":"2011","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.clinthera.2015.11.007_bib69","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1093\/cid\/cir921","article-title":"Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin","volume":"54","author":"Baquir","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib70","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/AAC.49.1.148-152.2005","article-title":"Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose","volume":"49","author":"Fetterly","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib71","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/AAC.47.6.1907-1911.2003","article-title":"Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis","volume":"47","author":"Cabellos","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib72","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1093\/cid\/cis001","article-title":"In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans","volume":"54","author":"Ambrose","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib73","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1128\/AAC.00029-11","article-title":"Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial","volume":"55","author":"Dunbar","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib74","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0091270005280378","article-title":"Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide","volume":"45","author":"Buckwalter","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.11.007_bib75","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/0091270008330162","article-title":"Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment","volume":"49","author":"Marbury","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.11.007_bib76","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1128\/AAC.00020-07","article-title":"Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits","volume":"51","author":"Solon","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib77","doi-asserted-by":"crossref","unstructured":"Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother. 2005;55:ii31\u2013ii35.","DOI":"10.1093\/jac\/dki006"},{"key":"10.1016\/j.clinthera.2015.11.007_bib78","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib79","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.01264-06","article-title":"In vivo pharmacodynamic activity of the glycopeptide dalbavancin","volume":"51","author":"Andes","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.11.007_bib80","unstructured":"FDA. FDA Briefing Document, NDA 021833. Advisory committee meeting: March 31, 2014. http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/ucm390788.htm; accessed May 31, 2015."},{"key":"10.1016\/j.clinthera.2015.11.007_bib81","doi-asserted-by":"crossref","first-page":"e41870","DOI":"10.1371\/journal.pone.0041870","article-title":"Efficacy and safety of telavancin in clinical trials: A systematic review and meta-analysis","volume":"7","author":"Polyzos","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2015.11.007_bib82","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1093\/cid\/cir162","article-title":"New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: Do not let the perfect be the enemy of the good","volume":"52","author":"Corey","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib83","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib84","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/AAC.02330-13","article-title":"Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival","volume":"58","author":"Corey","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl2","key":"10.1016\/j.clinthera.2015.11.007_bib85","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1093\/cid\/civ536","article-title":"Telavancin hospital-acquired pneumonia trials: Impact of gram-negative infections and inadequate gram-negative coverage on clinical efficacy and all-cause mortality","volume":"61","author":"Lacy","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib86","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: The ASSURE study","volume":"14","author":"Styjewski","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib87","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.11.007_bib88","unstructured":"De la Pena A, Chien J, Geiser J, et al. Microbiological outcomes and pharmacokinetics of oritavancin in patients with Gram-positive bacteremia. Poster presented at: The 12th European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy; 2002"},{"key":"10.1016\/j.clinthera.2015.11.007_bib89","unstructured":"Loutit J, O'Riordan W, San Juan J, et al. Phase 2 trial comparing four regimens of oritavancin vs. comparator in the treatment of patients with S. aureus bacteremia. Poster presented at: The 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague\/Czech Republic; 2004"},{"issue":"3","key":"10.1016\/j.clinthera.2015.11.007_bib90","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/17460913.3.3.251","article-title":"Oritavancin: a potential weapon in the battle against serious gram-positive pathogens","volume":"3","author":"Crandon","year":"2008","journal-title":"Future Microbiol"},{"key":"10.1016\/j.clinthera.2015.11.007_bib91","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib92","doi-asserted-by":"crossref","unstructured":"Dunne MW, Puttagunta S, Giordano P, et al. Single dose treatment with dalbavancin for acute bacterial skin and skin structure infection. Poster presented at: Infectious Diseases Week (IDWeek); San Diego, CA; 2015","DOI":"10.1093\/ofid\/ofv133.502"},{"key":"10.1016\/j.clinthera.2015.11.007_bib93","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.11.007_bib94","series-title":"Orbactiv [package insert]","year":"2014"},{"key":"10.1016\/j.clinthera.2015.11.007_bib95","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2146\/ajhp100011","article-title":"Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration","volume":"67","author":"Kumar","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2015.11.007_bib96","unstructured":"Dunne MW, Das AF, Puttagunat S. An analysis of the safety profile of dalbavancin from the phase 2\/3 clinical program [1334]. Poster presented at: Infectious Diseases Week; San Francisco, CA; 2013"},{"key":"10.1016\/j.clinthera.2015.11.007_bib97","series-title":"Dalvance [package insert]","year":"2014"},{"key":"10.1016\/j.clinthera.2015.11.007_bib98","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815012369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815012369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T16:03:13Z","timestamp":1582560193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815012369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":98,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0149291815012369"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.11.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}